GRAIL, Inc.GRAL決算レポート
Nasdaq · biotechnology industry
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Illumina, Inc. | 14.50% | 4.5M | — | 2024-08-14 |
| Sessa | 9.66% | 3.0M | — | 2024-11-14 |
| PRIMECAP Management Company | 7.03% | 2.2M | — | 2024-11-12 |
| CRCM Opportunity Fund III, LP | 1.28% | 397.4K | 変動なし | 2024-09-30 |
インサイダー取引
Net 90d: −$15.48M · buys $0 / sells $15.48M期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | SUMME GREGORY L | Director | Grant | 631 | $49.79 | $31.4K |
| 2026-04-15 | CHASE WILLIAM J | Director | Grant | 408 | $49.79 | $20.3K |
| 2026-04-15 | MIZELL STEVEN | Director | Grant | 396 | $49.79 | $19.7K |
| 2026-04-08 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 45.8K | $49.92 | $2.29M |
| 2026-04-08 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 123.5K | $49.92 | $6.16M |
| 2026-04-08 | Ofman Joshua J. | President | Sell (open market) | 61.7K | $49.92 | $3.08M |
| 2026-03-09 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 7.2K | $47.93 | $345.2K |
| 2026-03-09 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 258 | $46.73 | $12.1K |
| 2026-03-09 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 2.4K | $47.93 | $115.4K |
| 2026-03-09 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 85 | $46.74 | $4.0K |
1–10 of 23
1 / 3 ページ